NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT
Post# of 175
(Total Views: 47)
Posted On: 06/13/2025 5:41:47 PM
NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reported Q1 2025 Results, Advanced Toward Commercialization Following VALID-ECG Study Success
HeartBeam (NASDAQ: BEAT) reported financial results and operational highlights for the first quarter of 2025, marking significant progress toward commercialization of its 12-lead ECG synthesis software. The company successfully met clinical endpoints in its VALID-ECG pivotal study, demonstrating a 93.4% diagnostic agreement with standard ECGs, and engaged in productive discussions with the FDA on its 510(k) submission.
During the quarter, HeartBeam entered a strategic collaboration with AccurKardia to integrate its FDA-cleared AccurECG(TM) software into HeartBeam’s compact, cable-free cardiac device. The partnership was expected to accelerate product development and improve access to rapid arrhythmia diagnosis. The company also expanded its intellectual property portfolio with two new U.S. patents, bringing its total to 20 issued and 34 pending or allowed globally.
On the financial front, HeartBeam reported a net loss of $5.5 million for the quarter, primarily due to increased R&D investment. The company closed a public offering in February 2025, raising $11.5 million in gross proceeds. As of March 31, 2025, HeartBeam held $8.2 million in cash, cash equivalents, and short-term investments, and remained focused on achieving FDA clearance and launching commercialization efforts, including a pilot study for ischemia and heart attack detection later in the year.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://nnw.fm/BEAT
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
HeartBeam (NASDAQ: BEAT) reported financial results and operational highlights for the first quarter of 2025, marking significant progress toward commercialization of its 12-lead ECG synthesis software. The company successfully met clinical endpoints in its VALID-ECG pivotal study, demonstrating a 93.4% diagnostic agreement with standard ECGs, and engaged in productive discussions with the FDA on its 510(k) submission.
During the quarter, HeartBeam entered a strategic collaboration with AccurKardia to integrate its FDA-cleared AccurECG(TM) software into HeartBeam’s compact, cable-free cardiac device. The partnership was expected to accelerate product development and improve access to rapid arrhythmia diagnosis. The company also expanded its intellectual property portfolio with two new U.S. patents, bringing its total to 20 issued and 34 pending or allowed globally.
On the financial front, HeartBeam reported a net loss of $5.5 million for the quarter, primarily due to increased R&D investment. The company closed a public offering in February 2025, raising $11.5 million in gross proceeds. As of March 31, 2025, HeartBeam held $8.2 million in cash, cash equivalents, and short-term investments, and remained focused on achieving FDA clearance and launching commercialization efforts, including a pilot study for ischemia and heart attack detection later in the year.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://nnw.fm/BEAT
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)